183 related articles for article (PubMed ID: 34080493)
1. Clinical symptoms and blood concentration of new psychoactive substances (NPS) in intoxicated and hospitalized patients in the Budapest region of Hungary (2018-19).
Institóris L; Kovács K; Sija É; Berkecz R; Körmöczi T; Németh I; Elek I; Bakos Á; Urbán I; Pap C; Kereszty É
Clin Toxicol (Phila); 2022 Jan; 60(1):18-24. PubMed ID: 34080493
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and
Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Synthetic Cannabinoid Metabolites in Human Blood in the Absence of Parent Compounds: A Stability Assessment.
Krotulski AJ; Bishop-Freeman SC; Mohr ALA; Logan BK
J Anal Toxicol; 2021 Feb; 45(1):60-68. PubMed ID: 32435808
[TBL] [Abstract][Full Text] [Related]
4. 5F-MDMB-PICA metabolite identification and cannabinoid receptor activity.
Truver MT; Watanabe S; Åstrand A; Vikingsson S; Green H; Swortwood MJ; Kronstrand R
Drug Test Anal; 2020 Jan; 12(1):127-135. PubMed ID: 31461219
[TBL] [Abstract][Full Text] [Related]
5. Fatal intoxication with new synthetic cannabinoids 5F-MDMB-PICA and 4F-MDMB-BINACA-parent compounds and metabolite identification in blood, urine and cerebrospinal fluid.
Tokarczyk B; Jurczyk A; Krupińska J; Adamowicz P
Forensic Sci Med Pathol; 2022 Dec; 18(4):393-402. PubMed ID: 35699867
[TBL] [Abstract][Full Text] [Related]
6. The synthetic cannabinoid 5F-MDMB-PICA: A case series.
Kleis J; Germerott T; Halter S; Héroux V; Roehrich J; Schwarz CS; Hess C
Forensic Sci Int; 2020 Sep; 314():110410. PubMed ID: 32683270
[TBL] [Abstract][Full Text] [Related]
7. The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA.
Krotulski AJ; Cannaert A; Stove C; Logan BK
Drug Test Anal; 2021 Feb; 13(2):427-438. PubMed ID: 32997377
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues.
Longworth M; Banister SD; Boyd R; Kevin RC; Connor M; McGregor IS; Kassiou M
ACS Chem Neurosci; 2017 Oct; 8(10):2159-2167. PubMed ID: 28792725
[TBL] [Abstract][Full Text] [Related]
9. Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases.
Wagmann L; Stiller RG; Fischmann S; Westphal F; Meyer MR
Arch Toxicol; 2022 Oct; 96(10):2755-2766. PubMed ID: 35788413
[TBL] [Abstract][Full Text] [Related]
10. Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.
Mogler L; Franz F; Rentsch D; Angerer V; Weinfurtner G; Longworth M; Banister SD; Kassiou M; Moosmann B; Auwärter V
Drug Test Anal; 2018 Jan; 10(1):196-205. PubMed ID: 28371476
[TBL] [Abstract][Full Text] [Related]
11. Methyl (S)-2-(1-7 (5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (5F-MDMB-PICA) intoxication in a child with identification of two new metabolites (ultra-high-performance liquid chromatography-tandem mass spectrometry).
Szpot P; Nowak K; Wachełko O; Tusiewicz K; Chłopaś-Konowałek A; Zawadzki M
Forensic Toxicol; 2023 Jan; 41(1):47-58. PubMed ID: 36652054
[TBL] [Abstract][Full Text] [Related]
12. Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens.
Haschimi B; Mogler L; Halter S; Giorgetti A; Schwarze B; Westphal F; Fischmann S; Auwärter V
Drug Test Anal; 2019 Sep; 11(9):1377-1386. PubMed ID: 31228224
[TBL] [Abstract][Full Text] [Related]
13. NPS detection in prison: A systematic literature review of use, drug form, and analytical approaches.
Vaccaro G; Massariol A; Guirguis A; Kirton SB; Stair JL
Drug Test Anal; 2022 Aug; 14(8):1350-1367. PubMed ID: 35355411
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats.
Krotulski AJ; Garibay N; Walther D; Walton SE; Mohr ALA; Logan BK; Baumann MH
Neuropharmacology; 2021 Nov; 199():108800. PubMed ID: 34547333
[TBL] [Abstract][Full Text] [Related]
15. Linking in vitro and ex vivo CB
Janssens LK; Hudson S; Wood DM; Wolfe C; Dargan PI; Stove CP
Arch Toxicol; 2022 Nov; 96(11):2935-2945. PubMed ID: 35962200
[TBL] [Abstract][Full Text] [Related]
16. Focusing on the 5F-MDMB-PICA, 4F-MDMB-BICA synthetic cannabinoids and their primary metabolites in analytical and pharmacological aspects.
Dvorácskó S; Körmöczi T; Sija É; Bende B; Weiczner R; Varga T; Ilisz I; Institóris L; Kereszty ÉM; Tömböly C; Berkecz R
Toxicol Appl Pharmacol; 2023 Jul; 470():116548. PubMed ID: 37182749
[TBL] [Abstract][Full Text] [Related]
17. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.
Cabanlong CV; Russell LN; Fantegrossi WE; Prather PL
Toxicol Sci; 2022 Apr; 187(1):175-185. PubMed ID: 35201352
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.
Glatfelter GC; Partilla JS; Baumann MH
Neuropsychopharmacology; 2022 Mar; 47(4):924-932. PubMed ID: 34802041
[TBL] [Abstract][Full Text] [Related]
19. The role of illicit, licit, and designer drugs in the traffic in Hungary.
Institóris L; Hidvégi E; Dobos A; Sija É; Kereszty ÉM; Tajti LB; Somogyi GP; Varga T
Forensic Sci Int; 2017 Jun; 275():234-241. PubMed ID: 28412575
[TBL] [Abstract][Full Text] [Related]
20. Metabolism studies of 4'Cl-CUMYL-PINACA, 4'F-CUMYL-5F-PINACA and 4'F-CUMYL-5F-PICA using human hepatocytes and LC-QTOF-MS analysis.
Stalberga D; Ingvarsson S; Bessa G; Maas L; Vikingsson S; Persson M; Norman C; Gréen H
Basic Clin Pharmacol Toxicol; 2023 Mar; 132(3):263-280. PubMed ID: 36544361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
